Publication:
The effects of different hormone replacement treatment regimens on tear function, intraocular pressure and lens opacity

dc.contributor.buuauthorUncu, Gürkan
dc.contributor.buuauthorAvcı, Remzi
dc.contributor.buuauthorKaymaz, Cafer
dc.contributor.buuauthorUncu, Yeşim
dc.contributor.buuauthorDevelioğlu, Osman Haldun
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentKadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.contributor.orcid0000-0002-5225-4403
dc.contributor.researcheridD-9597-2016
dc.contributor.scopusid6603716169
dc.contributor.scopusid7004838001
dc.contributor.scopusid8892370600
dc.contributor.scopusid6603750027
dc.contributor.scopusid6701315440
dc.date.accessioned2022-03-23T11:00:15Z
dc.date.available2022-03-23T11:00:15Z
dc.date.issued2002-09
dc.descriptionBu çalışma, 12-17 Ocak 2002 tarihleri arasında Seattle[ABD]'da düzenlenen 58. Annual Meeting of the American Society for Reproductive Medicine'de bildiri olarak sunulmuştur.
dc.description.abstractObjective. Estrogen may have adverse effects on the ocular surface, intraocular pressure (IOP), lens opacity and tear function. The aim of the present study was to elucidate the effects of different hormone replacement therapy (HRT) protocols on tear function, IOP and lens opacity. Design and setting. This was a prospective, uncontrolled study carried out at the Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Uludaǧ University, Turkey. Patients and interventions. Thirty postmenopausal patients who had spontaneous or surgical menopause for at least 1 year and were not taking any medications were assigned to one of three groups. Group 1 comprised 19 patients (n = 38 observations) given conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg (Premelle 2.5®) daily; Group 2 contained six patients (n = 12 observations) given tibolone 2.5 mg (Livial®) daily; and Group 3 comprised five patients (n = 10 observations) treated with estradiol patch, 3.9 mg/12 cm2 (Climara®). Tear function, evaluated with Schirmer's test, IOP and lens opacity were determined before treatment and at 6 and 12 months of treatment. Results. Mean Schirmer's test score in each group and all eyes (n = 60) did not change significantly after 6 months of treatment but decreased significantly at 12 months. The percentage decrease in tear function was greatest in the estrogen-only group (Group 3). Mean IOP did not change significantly in Groups 1 and 2; however, in Group 3, IOP showed a statistically significant decrease from 14.63 ± 0.84 mmHg before treatment to 12.60 ± 0.68 mmHg (mean ± standard error) at the end of treatment. Lens opacity in women of all groups did not change during treatment. Conclusions. HRT decreased tear production, the decrease being greater in the estrogen- only group. Woman who are taking or considering HRT should be informed of the potential increased risk of dry eye syndrome with this therapy. In addition, estrogen-only treatment decreased IOP while estrogen plus progesterone and tibolone had no effect. HRT did not affect lens opacity after 12 months of treatment.
dc.description.sponsorshipAmerican Society of Reproductive Medicine
dc.identifier.citationUncu, G. vd. (2002). "The effects of different hormone replacement treatment regimens on tear function, intraocular pressure and lens opacity." Fertility and Sterility, 78(3), 98-99.
dc.identifier.endpage99
dc.identifier.issn0015-0282
dc.identifier.issue3
dc.identifier.scopus2-s2.0-33750473043
dc.identifier.startpage98
dc.identifier.urihttps://doi.org/10.1016/S0015-0282(02)03641-5
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S0015028202036415
dc.identifier.urihttp://hdl.handle.net/11452/25302
dc.identifier.volume78
dc.identifier.wos000178239400261
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherElsevier Science
dc.relation.journalFertility and Sterility
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectObstetrics & gynecology
dc.subjectReproductive biology
dc.subjectDry eye syndrome
dc.subjectHormone replacement therapy
dc.subjectIntraocular pressure
dc.subjectLens opacity
dc.subjectSchirmer's test
dc.subjectLivial
dc.subjectPremelle
dc.subjectClimara
dc.subject.emtreeCataract
dc.subject.emtreeConjugated estrogen plus medroxyprogesterone acetate
dc.subject.emtreeEstradiol
dc.subject.emtreeTibolone
dc.subject.emtreeAdult
dc.subject.emtreeArticle
dc.subject.emtreeHuman
dc.subject.emtreeControlled study
dc.subject.emtreeDrug effect
dc.subject.emtreeDry eye
dc.subject.emtreeFemale
dc.subject.emtreeHormone substitution
dc.subject.emtreeHospital department
dc.subject.emtreeIntraocular hypotension
dc.subject.emtreeMenopausal syndrome
dc.subject.emtreeIntraocular hypertension
dc.subject.emtreeIntraocular pressure
dc.subject.emtreeLacrimation
dc.subject.emtreePostmenopause
dc.subject.emtreePriority journal
dc.subject.emtreeSchirmer test
dc.subject.emtreeTurkey (republic)
dc.subject.meshMenopause
dc.subject.meshCataract
dc.subject.meshEstrogens
dc.subject.meshFemale
dc.subject.meshHormone replacement therapy
dc.subject.meshHumans
dc.subject.meshIntraocular pressure
dc.subject.meshMedroxyprogesterone 17-acetate
dc.subject.meshMiddle aged
dc.subject.meshNorpregnenes
dc.subject.meshTears
dc.subject.scopusMeibomian Glands; Intraocular Pressure; Open Angle Glaucoma
dc.subject.wosObstetrics & gynecology
dc.subject.wosReproductive biology
dc.titleThe effects of different hormone replacement treatment regimens on tear function, intraocular pressure and lens opacity
dc.typeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Kadın Hastalıkları ve Doğum Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: